Reckitt Benckiser Group plc (OTCMKTS:RBGLY - Get Free Report) has earned an average recommendation of "Buy" from the seven ratings firms that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and three have issued a strong buy rating on the company.
RBGLY has been the subject of a number of research analyst reports. Sanford C. Bernstein cut Reckitt Benckiser Group from a "strong-buy" rating to a "hold" rating in a report on Monday, November 4th. HSBC raised Reckitt Benckiser Group from a "hold" rating to a "buy" rating in a report on Wednesday, December 11th. Hsbc Global Res raised Reckitt Benckiser Group from a "hold" rating to a "strong-buy" rating in a report on Wednesday, December 11th. Finally, Barclays cut Reckitt Benckiser Group from an "overweight" rating to an "equal weight" rating in a report on Tuesday, February 4th.
Check Out Our Latest Report on Reckitt Benckiser Group
Reckitt Benckiser Group Trading Down 0.6 %
OTCMKTS RBGLY traded down $0.08 during midday trading on Thursday, hitting $13.33. The company had a trading volume of 235,675 shares, compared to its average volume of 247,016. The company has a debt-to-equity ratio of 0.97, a current ratio of 0.69 and a quick ratio of 0.47. Reckitt Benckiser Group has a twelve month low of $10.24 and a twelve month high of $15.03. The firm has a 50-day moving average price of $12.55 and a 200-day moving average price of $12.21.
About Reckitt Benckiser Group
(
Get Free ReportReckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Further Reading
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
